Ke Hui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ke Hui has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Chen Yang
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication - Dali Jiang
Department of Urology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication - Dalin He
Department of Urology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication - Haoqian Mmed Li
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication - Hongliang Mao
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication - Hongqing Cai
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 231
A dual-wavelength blue laser platform for integrated diagnosis and therapy in glioblastoma: preclinical evidence
- 14 September 2026
- Published by Springer Nature in Lasers in Medical Science
- Vol. 41 (1) , 231
Open AccessA dual-wavelength blue laser platform for integrated diagnosis and therapy in glioblastoma: preclinical evidence
- Open Access
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6955
Neurosurgical Resection for De Novo Brain Metastases from Non-Small Cell Lung Cancer: Real-World Evidence for Multidisciplinary Decision-Making
Background: Patients presenting with concurrent lung and brain lesions pose a unique diagnostic and therapeutic challenge. The role of neurosurgical resection in the management of de novo non-small-cell lung cancer brain metastases (NSCLC-BM) remains poorly defined. Methods: Consecutive patients undergoing resection for NSCLC-BM between February 2018 and October 2025 were retrospectively analyzed. De novo NSCLC-BM was defined as radiographic detection of pulmonary and intracranial lesions concurrently or within 1 month during the initial diagnostic work-up. Clinical characteristics and outcomes were compared between de novo and metachronous brain metastases (BM). Multivariable Cox regression identified factors associated with overall survival (OS). Factors associated with long-term postoperative survival in the de novo subgroup were further explored using Firth logistic regression. Results: Among 248 surgically treated patients, 113 (45.6%) presented with de novo BM. Compared with metachronous BM, de novo patients more frequently presented with symptomatic and multifocal intracranial disease. Among 73 de novo patients with evaluable survival, median postoperative OS was 57.0 months (95% CI, 22.9–not reached). Postoperative OS and intracranial progression-free survival (iPFS) did not differ significantly between the two groups, and de novo presentation was not independently associated with postoperative survival. Driver-positive status and lower intracranial tumor burden were associated with durable postoperative survival in the de novo subgroup. Conclusions: Neurosurgical resection represents a reasonable option for appropriately selected patients with de novo NSCLC-BM. These findings provide real-world evidence to inform multidisciplinary, individualized decision-making in patients presenting with concurrent lung and brain lesions.
- 8 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 6955
Open AccessNeurosurgical Resection for De Novo Brain Metastases from Non-Small Cell Lung Cancer: Real-World Evidence for Multidisciplinary Decision-Making
Background: Patients presenting with concurrent lung and brain lesions pose a unique diagnostic and therapeutic challenge. The role of neurosurgical resection in the management of de novo non-small-cell lung cancer brain metastases (NSCLC-BM) remains poorly defined. Methods: Consecutive patients undergoing resection for NSCLC-BM between February 2018 and October 2025 were retrospectively analyzed. De novo NSCLC-BM was defined as radiographic detection of pulmonary and intracranial lesions concurrently or within 1 month during the initial diagnostic work-up. Clinical characteristics and outcomes were compared between de novo and metachronous brain metastases (BM). Multivariable Cox regression identified factors associated with overall survival (OS). Factors associated with long-term postoperative survival in the de novo subgroup were further explored using Firth logistic regression. Results: Among 248 surgically treated patients, 113 (45.6%) presented with de novo BM. Compared with metachronous BM, de novo patients more frequently presented with symptomatic and multifocal intracranial disease. Among 73 de novo patients with evaluable survival, median postoperative OS was 57.0 months (95% CI, 22.9–not reached). Postoperative OS and intracranial progression-free survival (iPFS) did not differ significantly between the two groups, and de novo presentation was not independently associated with postoperative survival. Driver-positive status and lower intracranial tumor burden were associated with durable postoperative survival in the de novo subgroup. Conclusions: Neurosurgical resection represents a reasonable option for appropriately selected patients with de novo NSCLC-BM. These findings provide real-world evidence to inform multidisciplinary, individualized decision-making in patients presenting with concurrent lung and brain lesions.